LinXis B.V. logo

LinXis B.V.

LunXis B.V is a technology driven company developing ADC therapeutics utilizing platinum based Lx molecule for the target delivery of cancer drugs and antibodies. LunXis first Lx-based targeted drugs are in the late preclinical development stage.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.linxispharmaceuticals.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
De Boelelaan 1085cW&N building room N052
Amsterdam
Netherlands
Email
Contact Number
+31 6 14204520

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/linxispharmaceuticals
” connections=”true” suffix=””]

LinXis technology designs Lx-conjugates, a platinum complex that can be armed with highly potent drugs and allows for their facile coordination to targeting proteins or antibodies. Lx-platform also provides additional advantage of improved aqueous solubility of Lx-drug complexes compared to the free drug and Lx linker does not interfere with the chemical and biological properties of the drug and the antibody.

In March 2013, LinXis granted APO-T an exclusive worldwide development and commercialization rights of fully-human antibody- drug-conjugates developed through APO-Ts MAGE-HLA targeted antibodies and LinXis unique LX linker technology.